METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for men with Tough-to-Treat prostate cancer
Disease control CompletedThis study tested a new oral drug, CPI-1205, in combination with standard prostate cancer medications (enzalutamide or abiraterone/prednisone). It involved 175 men whose advanced prostate cancer had spread and was no longer responding to standard hormone therapy. The goal was to …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Finnish study maps the Real-World journey of advanced prostate cancer
Knowledge-focused CompletedThis study looked back at the medical records of over 1,000 men in Finland with advanced prostate cancer that had spread. Its goal was to understand who gets this disease, what treatments they receive, and how well those treatments work in everyday practice. By analyzing this rea…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC